Hologic — Q4 FY2008 Earnings Presentation
21 slides from Hologic's earnings presentation, Nov 17, 2008
Slide 1: Hologic, Inc. 2008 Fourth Quarter and Annual Performance
Exhibit 99.3 Hologic, Inc. 2008 Fourth Quarter and Annual Performance at September 27, 2008 • Financial results • Company highlights • First quarter and fiscal year 2009 outlook
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements regarding the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding: the Company’s backlog an
Slide 3: Q4-08 and FY-08 Overview
Q4-08 and FY-08 Overview Quarter and Year Ended September 27, 2008 Key Performance Metrics Q4 2008 FY 2008 Record Revenues $442.5 million $1,674.5 million • Up $239.9 million or 118.5% vs. Q4-07 • Up $936.1 million or 126.8% vs. FY-07 • Up $13.0 million or 3.0% vs. Q3-08 Net Income* Non-GAAP adjuste
Slide 4: Q4-08 and FY-08 Overview (continued)
Q4-08 and FY-08 Overview Quarter and Year Ended September 27, 2008 (continued) Additional Key Performance Metrics and FY 2008 Events: • Balance Sheet • Backlog of $360.4 million as of Sept. 27, 2008 (46.3% related to Breast Health and 49.4% related to Surgical and Diagnostics) • Term Loan Balance re
Slide 5: Acquisition of Third Wave Technologies in Q4'08
Acquisition of Third Wave Technologies in Q4’08 (acquired on July 24, 2008) The Transaction • $600M cash purchase – July 24, 2008 • $540M term loans to finance The Company • Patented molecular diagnostics platform • Two PMAs filed for HPV tests The HPV Market • $400M U.S. – 50% penetrated • $400M O.
Slide 6: Q4-08 Financial Performance
Q4-08 Financial Performance Quarter Ended September 27, 2008 (unaudited) ($s in millions) Non-GAAP* GAAP Q4-08 Q4-08 Q4-07 change Q3-08 change Revenues $442.5 $442.5 $202.6 118.4% $429.5 3.0% Gross margin 60.9% 54.3% 48.1% 6.2 57.0% (2.7) Operating Expenses $126.6 $328.8 $51.0 544.7% $137.1 139.8% P
Slide 7: Reconciliation of GAAP Net (Loss) Income and EPS to Non-GAAP Adjusted Net Income and EPS and Adjusted EBITDA
Reconciliation of GAAP Net (Loss) Income and EPS to Non-GAAP Adjusted Net Income and EPS and to Adjusted EBITDA (unaudited - in thousands, except EPS) Three Months Ended Three Months Ended September 27, 2008 September 29, 2007 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP REVENUES $ 442,512 $
Slide 8: Reconciliation to Adjusted EBITDA (continued)
Reconciliation of GAAP Net (Loss) Income and EPS to Non-GAAP Adjusted Net Income and EPS and to Adjusted EBITDA (continued) (unaudited - in thousands, except EPS) Three Months Ended September 27, 2008 Non-GAAP adjusted net income $ 77,211 Adjustments Interest expense, net 19,011 Provision for income
Slide 9: Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted Net Income, Twelve Months
Reconciliation of GAAP Net (Loss) Income and EPS to Non-GAAP Adjusted Net Income and Non-GAAP Adjusted EPS (unaudited - in thousands, except EPS) Twelve Months Ended Twelve Months Ended September 27, 2008 September 29, 2007 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP REVENUES $ 1,674,498 $ -
Slide 10: Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted Net Income - Continued
Reconciliation of GAAP Net (Loss) Income and EPS to Non-GAAP Adjusted Net Income and Non- GAAP Adjusted EPS - Continued (unaudited) The Company has presented the following non-GAAP financial measures: adjusted net income; adjusted EPS; and adjusted EBITDA. As set forth in the applicable reconciliati
Slide 11: Consolidated Balance Sheet Data
Consolidated Balance Sheet Data At Quarter End (unaudited - in millions) September 27, 2008 September 29, 2007 Cash $99.3 $100.4 Working Capital 352.7 220.6 Total Assets $8,134.6 $1,066.3 Long Term Liabilities 3,151.5 82.0 Total Liabilities 3,492.4 260.6 Stockholders' Equity $4,642.3 $805.7 Sound ba
Slide 12: Full Field Digital Mammography: Number of Selenias Sold
Full Field Digital Mammography Number of Selenias Sold* Selenia Highlights: 555 sold in FY06 1,189 sold in FY07 452 418 429 1,683 sold in FY08 384 351 328 282 228 193 154 97 111 54 64 71 3 11 16 27 27 35 37 44 50 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2003 2004 2005
Slide 13: MQSA U.S. Scorecard
MQSA U.S. Scorecard* (Mammography Quality Standards Act of 1992) Total Certified Facilities 8,827 Total Accredited Units 13,360 Certified Facilities with FFDM Units 3,896 44.1% Accredited FFDM Units 5,913 44.3% Total U.S. Annual Mammography Procedures 36.3 million Hologic U.S. Installed Base (as of
Slide 14: Q4-08 Segment Highlights: Total Breast Health
Q4-08 Segment Highlights Total Breast Health (Includes Mammography, R2, Suros, Mammopad, DRC, AEG and MammoSiteproducts) (unaudited) ($s in millions) Q4-08 Q4-07 % change Q3-08 % change Revenues $221.0 $177.0 24.9% $219.5 0.7% Gross margin 49.5% 51.4% (1.9) 51.5% (2.0) Operating income $54.3 $48.1 1
Slide 15: Q4-08 Segment Highlights: Diagnostics
Q4-08 Segment Highlights Diagnostics (Includes ThinPrep, Full Term and Third Wave products) (unaudited) ($s in millions) Q4-08 Q4-07 % change Q3-08 % change Revenues $133.7 $126.6 5.6% Gross margin 58.9% - New Segment 62.4% (3.5) Operating (loss) income ($163.2) $35.8 (555.9%) th 4 quarter highlight
Slide 16: Q4-08 Segment Highlights: GYN Surgical
Q4-08 Segment Highlights GYN Surgical (Includes NovaSure and Adiana products) (unaudited) ($s in millions) Q4-08 Q4-07 % change Q3-08 % change Revenues $59.7 $56.3 6.0% Gross margin 70.5% - New Segment 74.0% (3.5) Operating income $18.2 $12.2 49.2% th 4 quarter highlights: • GYN Surgical revenues re
Slide 17: Q4-08 Segment Highlights: Skeletal Health
Q4-08 Segment Highlights Skeletal Health (Includes Osteoporosis, Mini C-arm, Extremity MRI and General Radiography products) (unaudited) ($s in millions) Q4-08 Q4-07 % change Q3-08 % change Revenues $28.1 $25.6 9.8% $27.1 3.7% Gross margin 36.3% 25.4% 10.9 40.5% (4.2) Operating (loss) income $2.2 ($
Slide 18: GAAP Guidance for Q1-09
GAAP Guidance for Q1-09 (Quarter ending December 27, 2008) Q1 Q4 Q1 2009 ($s in millions, 2008 2008 Guidance Commentary except EPS) Actual Actual Revenues $371.4 $442.5 $441 - $443 Includes current core products only- no contribution from PMA products awaiting FDA approval. Gross margins 45.2% 54.3%
Slide 19: GAAP Guidance for 2009
GAAP Guidance for 2009 (Fiscal Year ending September 26, 2009) ($s in millions, Fiscal Fiscal 2009 Commentary except EPS) 2008 Guidance Actual Revenues Fiscal 2009 revenues are expected to increase to between $1.825 billion to $1.850 billion, $1,674.5 $1,825 - driven primarily by an increase in reve
Slide 20: Reconciliation of Future Non-GAAP Adjusted Earnings and EPS to GAAP
Reconciliation of Future Non-GAAP Adjusted Earnings and Earnings per Share to GAAP Three Months Ended Diluted Earnings Twelve Months Ended Diluted Earnings December 27, 2008 Shares per Share September 26, 2009 Shares per Share (In thousands, except per share amounts) Projected GAAP net income $42,30
Slide 21: Q4 and FY '08 Summary
Q4 and FY ’08 Summary • Strong Results – Revenues and earnings guidance met or exceeded – Record Selenia full field digital mammography systems installed and recognized as revenue – First Selenia Dimensions “Tomosynthesis/3-D” digital mammography systems installed and recognized as revenue in Q4 in